Progress in treatment of decompensated heart failure 失代偿性心衰治疗研究进行时
The 12-month all-cause mortality was 27.4 %, and was higher among those with decompensated congestive hf ( 33.5 % ) than the de novo hf group 12个月的全因死亡率为27.4%,并且失代偿性充血性心力衰竭组(33.5%)高于新发心衰组。
Context because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival 背景:由于急性失代偿性心衰能导致实际发病率和病死率上升,这就要求药物不仅能改善血液流变学和减轻症状,而且不会相反地影响生存率。
Design, setting, and patients the survival of patients with acute heart failure in need of intravenous inotropic support ( survive ) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support 设计,设定和病人:将患有急性心衰并需要静脉收缩药物支持的病人随机分组,双盲实验条件下比较1327名患有急性失代偿性心衰并需要收缩药物支持的病人在静脉注射左西孟旦或多巴酚丁胺后的效力和安全性。